KPV Reconstitution Calculator

No. KPV is not FDA-approved for any indication and has no human clinical trial data. The evidence base is preclinical: antipyretic effects in rabbits (animal), reduced intestinal inflammation in murine colitis models (animal), and in-vitro anti-inflammatory activity. As an unapproved peptide, it is marketed through a largely unregulated supply chain with documented risks of mislabeling and contamination.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH positions 11–13). It retains α-MSH's anti-inflammatory activity and binds melanocortin-1 receptor (MC1R) on melanocytes; receptor engagement activates cAMP–tyrosinase (TYR) signaling and raises endogenous melanin production. Core mechanisms (in-vitro/mechanistic): inhibition of NF-κB activation, suppression of pro-inflammatory cytokines, and stimulation of IL-10. In intestinal epithelium, KPV is transported by the peptide transporter PepT1, which is upregulated in inflamed colon tissue, conferring gut selectivity. It suppresses ROS/AKT/mTOR-related lipogenic signaling in metabolic tissues (in-vitro).

Depends on target. Free oral KPV reduced DSS-induced colitis in mice via PepT1 uptake but is vulnerable to gastrointestinal degradation: under acid, alkali, or oxidative stress it degrades to lys-pro-diketopiperazine. Delivery systems overcome this: hyaluronic-acid nanoparticles in chitosan/alginate hydrogel improved mucosal healing and TNF-α suppression versus plain KPV, and ROS-responsive prodrugs achieved 3.8-fold higher colonic accumulation with efficacy at a 20-fold lower dose. Injectable subcutaneous KPV is the common systemic route in community practice (practitioner consensus). Topical hydrogels show anti-inflammatory and anti-MRSA activity in wound/mucositis contexts; transdermal iontophoresis across microporated human skin is feasible ex vivo. Practical guidance: oral for GI/mucosal complaints; subcutaneous for systemic or non-GI effects; topical for skin/surface lesions (community protocol).

There is no human dose-response data. Effective in-vitro concentrations are 50–100 μg/mL; animal oral doses were formulation-dependent and do not translate to human mg/kg equivalents. Community protocols commonly use 200–500 μg subcutaneously daily (weight-scaled ~3–7 μg/kg), or roughly 500–1,000 μg/day orally given degradation losses (practitioner consensus). No validated therapeutic range exists.

No. There are no reproductive safety data. KPV acts on melanocortin receptors and suppresses core inflammatory and metabolic signaling; effects on fetal development and lactation are completely unstudied. Avoid during pregnancy and breastfeeding.

Unknown. No long-term human safety data exist, and chronic peptide use carries poorly defined risks. Animal studies used short-term administration windows. Community practice typically cycles KPV for 4–8 weeks, but no evidence defines a safe maximum duration (practitioner consensus).

A 2026 comparative review found BPC-157 is primarily angiogenic and vasculoprotective; thymosin beta-4/TB-500 acts mainly through actin regulation and cell migration; KPV's profile is anti-inflammatory via NF-κB modulation. KPV is much smaller (3 residues vs 15+ and 43), and uniquely has a defined intestinal uptake transporter (PepT1), giving it the strongest preclinical rationale for gut inflammation. For musculoskeletal/tendon repair, BPC-157 and TB-500 have more accumulated (though still preclinical) evidence; for mucosal, gut, and skin inflammation, KPV's mechanism is better matched.

Lyophilized powder should be stored refrigerated (2–8°C); the dry form is relatively stable. Reconstituted aqueous KPV degrades under acid, alkali, and oxidative conditions, forming lys-pro-diketopiperazine. Use reconstituted solutions within days to a few weeks, keep refrigerated between doses, and discard if turbid or precipitated (community protocol). No published human pharmacokinetic data support specific shelf-life claims.